You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Dow
Merck
Mallinckrodt
Harvard Business School

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,974,534

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,974,534
Title:Suture anchor with soft anchor of electrospun fibers
Abstract: A flexible anchor for coupling a suture to a bone is provided. The anchor is composed of non-woven electrospun fibers and has an elongate tubular body that extends from a first end to a second end. The anchor is configured to receive a suture that enters the anchor through a first aperture and exits the anchor through a second aperture. When free ends of the suture are pulled, the anchor transitions from a first configuration to a second anchoring configuration.
Inventor(s): Troxel; Karen S. (Warsaw, IN), Stone; Kevin T. (Winona Lake, IN)
Assignee: Biomet Sports Medicine, LLC (Warsaw, IN)
Application Number:14/675,082
Patent Claims:1. A suture assembly comprising: a flexible anchor having an elongate hollow tubular sheath body defining a longitudinal passage extending from a first end to a second end, the flexible anchor being composed of non-woven electrospun fibers; and a suture comprising a first free end and a second free end, wherein the suture is passed into the flexible anchor through a first opening and is passed out of the flexible anchor through a second opening and extends along the longitudinal passage within the hollow elongate tubular sheath body from the first opening to the second opening, such that the first and second free ends of the suture are external to the flexible anchor, wherein the suture assembly is configured to be inserted into a bore in a bone, and wherein the suture assembly is configured to switch from a first configuration to a second locking configuration when the anchor is inserted into the bore prepared in the bone and the free ends are pulled in a direction that is generally coaxial with and away from bore.

2. The suture assembly according to claim 1, wherein switching from a first configuration to a second configuration comprises changing shape from a first profile to a second profile.

3. The suture assembly according to claim 1, wherein the first profile is suitable for carrying the suture assembly into the bore and the second profile is an anchoring mass that retains the flexible anchor in the bore.

4. The suture assembly according to claim 3, wherein the anchoring mass includes a width in a direction perpendicular to a longitudinal axis of the bore greater than the first profile.

5. The suture assembly according to claim 1, wherein the free ends of the suture are configured to secure a soft tissue, second bone, or structure to the bone after the suture assembly is switched to the second locking configuration.

6. An anchor for coupling a suture to a bone, the anchor comprising a hollow elongate tubular sheath body extending from a first end to a second end and defining a longitudinal passage between the first end and the second end, wherein the anchor comprises non-woven electrospun fibers having a diameter of from about 0.1 .mu.m to about 10 .mu.m, the electrospun fibers including a modifying agent, a biological agent, an antimicrobial agent, or a combination thereof.

7. The anchor according to claim 6, wherein the anchor comprises a hollow elongate tubular body that defines a cylindrical wall having a thickness of from about 0.1 mm to about 5 mm and an internal passage that extend from the first end to the second end.

8. The anchor according to claim 6, wherein the tubular body is solid and configured to be pierced inward by a needle at a first location to generate a first opening, to have the needle pass through an interior portion of the solid tubular body, and to be pierced outward by the needle at a second location to generate a second opening.

9. The anchor according to claim 6, wherein the tubular body is hollow, and the tubular body comprises a first opening or aperture at a first location and a second opening or aperture at a second location.

10. The anchor according to claim 6, wherein the anchor is a component of a suture assembly comprising a suture with first and second ends and the anchor, wherein the suture passes into the anchor through a first opening and out of the anchor through a second opening, such that the two free ends are external to the tubular body of the anchor.

11. The anchor according to claim 10, wherein the anchor is configured to be in a first insertion profile when being inserted into a prepared bore in a bone, and to be in a second locking profile within the bore when the free ends of the suture are pulled in a direction that is generally coaxial with and away from bore.

12. The anchor according to claim 6, wherein the electrospun fibers comprise a degradable polymer selected from the group consisting of fibrin, collagen, laminin, fibronectin, elastin, chitosan, gelatin, hyaluronan, albumin, dextran, pectin, starch, polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL, including epsilon caprolactone), polydioxanone (PDO), polyhdryoxybutyrate (PHB), poly(anhydrides), poly(trimethylene carbonate) (PTC), polyphophazenes, poly amino acids, poly(L-lysine), epsilon poly-lysine, poly(L-ornithine) (PLO), poly(L-glutamic acid-4-co-L-tyrosine) (PLEY), and mixtures thereof.

13. The anchor according to claim 6, wherein the electrospun fibers comprise a non-degradable polymer selected from the group consisting of polyesters, polycarbonate urethanes, polypropylene (PP), nylon, polyurethane (PU), polyester urethanes, polyetherurethanes, polyvinylchloride (PVC), polyethylene (PE), poly(tetrafluroethylene (PTFE), poly(methyl acrylate) (PMA), poly(methyl methacrylate (PMMA), ethylene-co-vinylacetate (EVA), poly(dimethylsiloxane) (PDMS), poly(ethylene terephthalate) (PET), poly(sulphone) (PS), poly(ethyleneoxide) (PEO), poly(ethyleneoxide-co-prpyleneoxide) (PEO-PPO), poly(vinylalcohol) (PVA), and mixtures thereof.

14. An anchor for coupling a suture to a bone, the anchor comprising a hollow elongate tubular sheath body defining a longitudinal passage extending from a first end to a second end, the anchor being configured to receive a suture that enters the anchor through a first aperture and exits the anchor through a second aperture and extends along the longitudinal passage within the hollow elongate tubular sheath body from the first aperture to the second aperture, wherein the anchor is configured to be inserted in a bore in a bone and wherein pulling free ends of the suture sets the anchor in an anchoring configuration when the anchor is inserted in the bore in the bone, wherein the anchor comprises a non-woven material.

15. The anchor according to claim 14, wherein the non-woven material comprises electrospun fibers with a diameter of from about 1 nm to about 50 .mu.m.

16. The anchor according to claim 15, wherein the electrospun fibers have a diameter that is near the size of collagen fibrils or collagen fiber bundles.

17. The anchor according to claim 16, wherein the fibers have a diameter of from about 0.1 .mu.m to about 10 .mu.m.

18. The anchor according to claim 15, wherein the electrospun fibers include at least one of a modifying agent for promoting cellular attachment; a biological agent for stimulating cell infiltration, promoting differentiation and maturation of repair tissue, or decreasing inflammation; or an antimicrobial agent selected from the group consisting of antifungal agents, antiviral agents, antibacterial agents, and combinations thereof.

19. The anchor according to claim 18, wherein the modifying agent is chitosan, gelatin, collagen, silk fibroin, polyethylene glycol, poly-1-lysine, epsilon poly-lysine, blood serum albumin, elastin, fibronectin, a biocompatible protein, or a combination thereof.

20. The anchor according to claim 18, wherein the modifying agent is an agent that provides osteoconductive and/or osteogenic properties to the electrospun fibers, wherein the agent is selected from the group consisting of tricalcium phosphate, hydroxyapatite, bioglass, and combinations thereof.

21. The anchor according to claim 18, wherein the biological agent is selected from the group consisting of immunomodulatory host defense proteins, immunomodulatory synthetic mimics of host defense proteins, bisphosphonates, parathyroid hormone, teriparatide, recombinant parathyroid hormone derivatives, parathyroid hormone fragments, strontium ranelate, phenamil, naringin, interleukin-1 receptor antagonist (IL-1ra), soluble interleukin-1 receptor II (sIL-1RII), soluble tumor necrosis factor-receptor 1 (sTNF-RI), soluble tumor necrosis factor-receptor 2 (sTNF-RII), fibroblast growth factor (FGF), bone morphogenetic growth factors (BMPs), insulin-like growth factor (IGF-I), epidermal growth factor EGF), hepatocyte growth factor (HGF), platelet-derived growth factor AB (PDGF-AB), platelet-derived growth factor BB (PDGF-BB), vascular endothelial growth factor (VEGF), transforming growth factor-.beta.1, (TGF-.beta. 1), and mixtures thereof.

Details for Patent 9,974,534

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial Biomet Sports Medicine, LLC (Warsaw, IN) 2039-02-26 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial Biomet Sports Medicine, LLC (Warsaw, IN) 2039-02-26 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial Biomet Sports Medicine, LLC (Warsaw, IN) 2039-02-26 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial Biomet Sports Medicine, LLC (Warsaw, IN) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Medtronic
Mallinckrodt
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.